Creator: Help Dementia Editorial Team
Published: 2026-04-23T12:20:24

Reviewed by the Help Dementia Editorial Team — our editors review every article for accuracy against guidance from the National Institute on Aging, the Alzheimer’s Association, and peer-reviewed sources.

New treatments sits at the center of this dementia and brain health question.

Yes, new treatments for Alzheimer’s disease are emerging and becoming available to patients, marking a significant shift after decades of limited options. In the past year alone, the FDA has approved multiple disease-modifying therapies that target the underlying biological processes driving cognitive decline, and dozens more are in clinical trials. For the first time, people with mild cognitive impairment or early-stage Alzheimer’s have access to infusions and injections designed to slow disease progression, rather than simply manage symptoms. Lecanemab, marketed as Leqembi, exemplifies this progress. A person with mild cognitive impairment might now receive a once-weekly injection at home starting in August 2025, or a once-every-four-weeks maintenance dose approved in January 2025—treatments that would have been impossible just a few years ago.

Donanemab, another monoclonal antibody approved by the FDA and now available in Europe, offers an intravenous infusion option every four weeks. While these drugs are not cures, they represent the first genuine disease-modifying interventions that show promise in slowing cognitive decline. The pipeline is robust. As of early 2026, 138 drugs are currently in 182 clinical trials worldwide, with 73% being disease-targeted therapies rather than symptom management alone. This momentum reflects renewed confidence in the amyloid hypothesis—the idea that clearing amyloid-beta plaques from the brain can slow Alzheimer’s progression—after decades of failed attempts.

What Are These Emerging Alzheimer’s Treatments?
FDA-Approved Treatments and What They Offer—and Don’t
What’s Coming Next—The Clinical Trial Pipeline
What Patients and Families Need to Know About Access and Eligibility
The Controversy Over How Much Benefit Is Real
Prevention—Testing Treatments in People Without Symptoms
Looking Ahead—What the Next Few Years May Bring
Conclusion

What Are These Emerging Alzheimer’s Treatments?

The new treatments approved and in development fall into two main categories: monoclonal antibodies that clear amyloid plaques, and tau-targeting therapies that address another hallmark protein implicated in neurodegeneration. Lecanemab and donanemab are both monoclonal antibodies developed through different mechanisms to attack amyloid-beta accumulation in the brain before it causes widespread damage. Lecanemab binds to amyloid protofibrils, while donanemab targets a different form of amyloid oligomers, illustrating how multiple approaches to the same underlying problem are advancing in parallel. Beyond these two approved options, the clinical trial pipeline includes trontinemab, now in Phase III trials, and BIIB080, a tau-targeting antisense oligonucleotide in Phase II development with FDA Fast Track designation.

This diversity matters because Alzheimer’s is not a single disease in a biological sense—different patients may have different ratios of amyloid and tau pathology, and the ability to target specific proteins could eventually enable more personalized treatment approaches. AXS-05, developed by Axsome Therapeutics, represents a different strategy altogether. Rather than targeting amyloid or tau, it addresses behavioral and psychiatric symptoms common in Alzheimer’s, particularly agitation and aggressiveness. The FDA scheduled its decision for April 30, 2026, under Priority Review, acknowledging that helping people manage behavioral symptoms can significantly improve quality of life and reduce caregiver burden.

What Are These Emerging Alzheimer's Treatments?

FDA-Approved Treatments and What They Offer—and Don’t

Lecanemab and donanemab have both received FDA approval, but their approval came with significant caveats and limitations. Both are indicated only for patients with mild cognitive impairment or mild dementia stage—not for moderate or advanced disease. They require regular infusions or injections, regular MRI brain imaging to monitor for amyloid-related imaging abnormalities (ARIA), which is a potential brain inflammation or microhemorrhage complication, and blood tests. The treatment is not a one-time therapy but an ongoing commitment, typically continuing for years. The infusion process itself can be burdensome. Donanemab requires monthly intravenous infusions lasting 20 minutes or more, and many infusion centers have limited availability.

Lecanemab initially required biweekly infusions before the August 2025 approval of once-weekly dosing made it more manageable. Even the newer once-monthly Leqembi regimen requires regular monitoring, and patients often experience amyloid-related imaging abnormalities—asymptomatic brain changes visible only on MRI that may require stopping the medication if they progress to symptomatic levels. A major limitation that has only recently come into sharp focus: the clinical benefit, while real, may be smaller than initially hoped. A Cochrane systematic review released in April 2026 analyzed 17 studies involving 20,342 participants and concluded that both donanemab and lecanemab show “trivial” effects on cognitive function and “small at best” effects on functional ability at 18 months. According to the review, while slowing cognitive decline by 35% sounds meaningful, the absolute difference in functional decline over 18 months may translate to only a few months of delayed symptom onset. Manufacturers like Eisai dispute these conclusions, pointing to longer-term data extending to four years and outcomes in tens of thousands of patients globally, but the debate highlights a critical question: How much benefit is enough to justify the cost, inconvenience, and risks?.

What’s Coming Next—The Clinical Trial Pipeline

The drug pipeline is substantial and diverse. Of the 138 drugs in 182 clinical trials globally as of early 2026, 30% are biological therapies and 43% are small molecule drugs—meaning pills rather than infusions or injections. This shift toward oral medications could potentially make treatment more accessible, though it also comes with the challenge of ensuring sufficient blood-brain barrier penetration so the drug reaches the brain in adequate concentration. Trontinemab represents continued refinement in the monoclonal antibody space. It is designed to further optimize amyloid-beta targeting and potentially reduce the side effect burden compared to earlier therapies.

BIIB080 takes a different approach by targeting tau pathology. Tau tangles are a hallmark of Alzheimer’s, and some researchers believe addressing tau accumulation could be equally or more important than amyloid targeting alone. BIIB080’s Fast Track designation from the FDA reflects genuine clinical need and promising early data. Beyond anti-amyloid and anti-tau approaches, the pipeline includes therapies targeting neuroinflammation, synaptic function, metabolic dysfunction, and vascular dysfunction. Some trials are exploring combination approaches—using an anti-amyloid drug alongside a tau-targeting therapy or anti-inflammatory agent. These multi-pronged approaches may eventually prove more effective than any single agent, though designing trials to test combinations adds significant complexity and time.

What's Coming Next—The Clinical Trial Pipeline

What Patients and Families Need to Know About Access and Eligibility

To receive lecanemab or donanemab, a patient must have documented mild cognitive impairment or mild dementia due to Alzheimer’s disease, confirmed with cognitive testing and often a PET scan or cerebrospinal fluid biomarker showing amyloid pathology. This is important to understand: having memory problems is not enough. A formal diagnosis with biomarker confirmation is required, which may involve visiting a memory clinic or neurologist and undergoing specialized imaging or lumbar puncture. Cost is a significant consideration. These therapies are expensive, with annual costs typically exceeding $25,000 before insurance considerations. Medicare covers them, but coverage and out-of-pocket costs vary by individual circumstances and supplemental insurance.

Commercial insurance coverage varies, and some patients are denied coverage based on age, kidney function, or other criteria. Many patients rely on patient assistance programs offered by manufacturers, but navigating these programs requires effort and time. The monitoring burden is substantial and often underestimated in early discussions. Patients and families should know that starting on lecanemab or donanemab means committing to regular MRI scans—often every six months to one year—to detect amyloid-related imaging abnormalities, regular blood tests, and ongoing clinic visits. Some patients experience ARIA symptoms like headaches, confusion, or microhemorrhages requiring hospitalization. For some patients, the treatment regimen itself becomes a source of stress and anxiety, counteracting the modest cognitive benefit.

The Controversy Over How Much Benefit Is Real

The April 2026 Cochrane review sent shockwaves through the Alzheimer’s community by challenging the narrative that these new drugs are a major breakthrough. The review found that cognitive benefit is “trivial”—meaning that while statistically measurable, the real-world difference in how patients function may be negligible. At 18 months, the group on lecanemab showed cognitive decline slowed by 35%, which sounds impressive, but the absolute difference translated to roughly 25% less cognitive decline on the tests used, not a reversal or halt of decline. Manufacturers have responded vigorously. Eisai and Eli Lilly point out that the Cochrane review excluded some relevant studies, focused on shorter-term outcomes, and did not account for recently published longer-term data showing continued benefits to four years in some patient populations.

Eisai also emphasizes that tens of thousands of patients globally are now taking lecanemab, and post-market data collection is ongoing. The company argues that the Cochrane review’s timing and conclusions may not reflect the full clinical picture, and that for some individual patients, even modest slowing of cognitive decline is meaningful and valuable. This controversy matters because it directly affects treatment decisions. Some patients and families will view even a modest delay in symptom progression as worthwhile, particularly if it preserves independence and decision-making capacity for a few additional months or years. Others may decide that the inconvenience, cost, side effect risk, and monitoring burden outweigh a benefit they perceive as minimal. There is no objectively “right” answer, which makes shared decision-making between patients, families, and physicians crucial.

The Controversy Over How Much Benefit Is Real

Prevention—Testing Treatments in People Without Symptoms

One of the most ambitious new directions in Alzheimer’s research is testing whether disease-modifying drugs can prevent cognitive decline entirely in people who have no symptoms but show biomarker evidence of amyloid pathology. The AHEAD Study is testing lecanemab in this population, enrolling cognitively normal older adults with amyloid plaques visible on PET scans. If prevention is possible, the impact could be enormous, potentially stopping Alzheimer’s before it ever starts.

However, prevention trials come with ethical complexity. Enrolling asymptomatic people in a long-term treatment trial exposes them to the same side effect risks and monitoring burdens, with the uncertain benefit of disease prevention rather than symptom improvement. The AHEAD Study participants understand this trade-off, but if lecanemab shows benefit in preventing cognitive decline in this population, it could shift the entire paradigm toward early biomarker-based intervention in healthy older adults.

Looking Ahead—What the Next Few Years May Bring

The approval of new treatments and the robust pipeline suggest that Alzheimer’s is transitioning from a disease with no disease-modifying options to one with multiple targeted approaches. The next phase of development will likely see attempts to improve tolerability (fewer side effects, less frequent dosing), expand indications to earlier or later disease stages, and develop oral medications that patients can take at home rather than undergoing regular clinic visits. Combination therapies are on the horizon.

Trials combining anti-amyloid and anti-tau drugs, or adding anti-inflammatory agents to amyloid-targeting therapy, may prove more effective than single agents alone. Personalized medicine approaches—using biomarker profiles to tailor treatment selection—could emerge as research clarifies which patient populations benefit most from which therapies. While none of these advances will be available imminently, the trajectory of Alzheimer’s drug development has fundamentally shifted from “no good options” to “multiple options with real but modest benefits and new options emerging.”.

Conclusion

New treatments for Alzheimer’s disease are indeed emerging and becoming available to patients. Lecanemab and donanemab represent genuine disease-modifying therapies approved by the FDA, and a robust pipeline of 138 drugs in clinical trials suggests continued innovation. These treatments can slow cognitive decline by a meaningful percentage, though the absolute benefit in terms of day-to-day functioning remains debated and may be smaller than patients initially hope.

The key for patients and families is to approach these new treatments with realistic expectations, careful consideration of eligibility and personal circumstances, and ongoing dialogue with healthcare providers. These therapies are not cures, and they are not appropriate for everyone, but for some people with early Alzheimer’s disease, they offer something unprecedented: a genuine opportunity to slow the disease’s progression. Combined with lifestyle factors like cognitive engagement, physical activity, cardiovascular health management, and social connection, new pharmacological treatments represent a more comprehensive approach to Alzheimer’s management than was previously possible.